VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Jonasch on the Potential of Immunotherapy for Sarcomatoid RCC

Eric Jonasch, MD
Published: Thursday, Jun 22, 2017



Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Sarcomatoid RCC is a difficult area to treat from an efficacy standpoint, explains Jonasch. Emerging data suggest that immuno-oncology agents might be useful for this patient population.

There are published data demonstrating that PD-L1 expression is higher with sarcomatoid RCC and raises the hypothesis that targeting PD-1/PD-L1 might be beneficial, states Jonasch.
 


Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Sarcomatoid RCC is a difficult area to treat from an efficacy standpoint, explains Jonasch. Emerging data suggest that immuno-oncology agents might be useful for this patient population.

There are published data demonstrating that PD-L1 expression is higher with sarcomatoid RCC and raises the hypothesis that targeting PD-1/PD-L1 might be beneficial, states Jonasch.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x